Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) "ACTIVE I"

Completed

Phase 3 Results

Summary of Purpose

The purpose of this study was to determine if Irbesartan compared to Placebo would reduce the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and death in patients with Atrial Fibrillation (AF) and with at least one major risk of vascular events.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 29 September 2010.

1 Jun 2003 4 Nov 2005 1 Aug 2009 1 Aug 2009 1 Sep 2010 24 Aug 2010
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available